ELVN — Enliven Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1672619 ·
Last close
$46.85
Market Cap
$3.45B
52W High
$62.32
52W Low
$14.78
ADV30
1,438,709
Next earnings
2026-11-11

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -36,045,000 -27,703,000 897,225,000 151,667,000 20,278,000
Jun 2026 0 — -37,209,000 -32,485,000 910,223,000 135,505,000 15,074,000
Mar 2026 0 — -27,823,000 -23,627,000 464,852,000 132,184,000 11,487,000
Dec 2025 0 — -34,285,000 -29,667,000 476,168,000 98,896,000 16,568,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-66,939,000
Investing CF
$-390,719,000
Financing CF
$473,726,000
CapEx
$-159,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.67
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-403,278,000
Inventory
—
Receivables
—
ST Investments
$759,650,000
EBIT TTM
$-124,413,000
Pretax Income TTM
$-105,927,000
Interest Exp TTM
—
Analysts
12

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -119,658,000 -103,694,000 476,168,000 16,568,000 459,600,000 -70,301,000
Dec 2024 0 -104,554,000 -89,024,000 325,760,000 15,915,000 309,845,000 -73,192,000
Dec 2023 0 -83,529,000 -71,584,000 271,867,000 25,961,000 245,906,000 -61,269,000
Dec 2022 0 -38,791,000 -37,662,000 83,298,000 160,123,000 -76,825,000 -32,077,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-105,927,000
OpCashFlow TTM
—
Assets (Latest)
$910,223,000
Forward EPS
$-2.14

Max Pain — expiry 2027-03-19 (volume-derived — Yahoo OI feed degraded)

max pain strike: $25.00 · spot: $44.89 · call volume: 194 · put volume: 60

Peers — same industry

TickerNameMarket CapLastDaily %
ARQT Arcutis Biotherapeutics, Inc. $3.46B $27.33 —
VKTX Viking Therapeutics, Inc. $3.43B $26.88 —
VRDN Viridian Therapeutics, Inc.\DE $3.41B $30.06 —
IRON Disc Medicine, Inc. $3.49B $76.57 —
PBLS Parabilis Medicines, Inc. $3.49B $28.25 —

News headlines (Yahoo Finance, 1h cache)

Enliven Therapeutics Stock In Focus After Wider Loss And FDA Trial Alignment
2026-11-07 16:13 · Yahoo
Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update
2026-11-05 21:05 · Yahoo
Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year
2026-10-14 20:30 · Yahoo
Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial
2026-10-07 15:21 · Yahoo
Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia
2026-10-06 20:05 · Yahoo
Enliven Therapeutics to Present at Upcoming Investor Conferences
2026-09-03 20:05 · Yahoo
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
2026-08-31 22:05 · Yahoo
Enliven Therapeutics (ELVN) Stock Looks Overvalued As Returns Surge But Book Value Lags
2026-07-04 06:10 · Yahoo
What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally
2026-06-27 16:23 · Yahoo
What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%
2026-06-27 19:56 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.